Katsuyuki Kiura
Okayama, 7008558, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 299 publications
Contribution of Interleukin-22 Binding Protein to the Development of Allergen-Induced Airway Hyperresponsiveness.
Journal: International journal of molecular sciences
Published: June 07, 2026
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment.
Journal: Current oncology (Toronto, Ont.)
Published: April 08, 2026
Correction: Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
Journal: Cureus
Published: October 20, 2025
TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.
Journal: Cancer science
Published: September 01, 2025
Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study.
Journal: Respiratory investigation
Published: April 02, 2025
Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
Journal: Cureus
Published: February 14, 2025
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation.
Journal: Molecular cancer therapeutics
Published: January 19, 2025
Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors.
Journal: International journal of clinical oncology
Published: December 26, 2024
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Journal: International journal of clinical oncology
Published: December 17, 2024
Last Updated: 09/26/2026